[BEP-chemotherapy in patients with testicular tumors--is it worthwhile?].
Since 1985 44 consecutive patients with testicular cancer have been treated with a modified BEP regimen. 70% had metastatic disease and 30% received adjuvant therapy. After mean follow-up of 26 (8-56) months, 91% of patients are alive and all are in remission. Chemotherapy-related side effects were alopecia (100%), myelosuppression (100%), nausea/vomiting (89%) and fever (66%). Patients reported nausea has been rare. It is concluded that BEP chemotherapy is a highly effective treatment which secures complete remission or cure even in patients with advanced metastatic disease. In retrospect the patients considered the treatment worthwhile despite the stress involved.
Medizinische Klinik C, Kantonsspital St. Gallen.
U
U
Hess
W F
WF
Jungi
R
R
Morant
L
L
Schmid
H J
HJ
Senn
K
K
Bandhauer
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D001855:Bone Marrow Diseases / Q000139:chemically induced; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005334:Fever / Q000139:chemically induced; D006801:Humans; D008171:Lung Diseases / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009422:Nervous System Diseases / Q000139:chemically induced; D012189:Retrospective Studies; D013736:Testicular Neoplasms / Q000188:drug therapy*
D001761:Bleomycin; D005047:Etoposide; D002945:Cisplatin
BEP-Chemotherapie bei Patienten mit Hodentumoren--Hat es sich gelohnt?